On December 3rd, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) We have obtained approval from the National Medical Products Administration (NMPA) of China to combine platinum based chemotherapy as neoadjuvant therapy and continue to use pembrolizumab monotherapy as adjuvant therapy after surgery for stage II, IIIA, and IIIB non-small cell lung cancer patients who can be surgically resected. Previously in China, pembrolizumab had obtained three indications for advanced non-small cell lung cancer.